Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price fell 7.6% on Tuesday. The stock traded as low as $3.90 and last traded at $3.8710. Approximately 3,077,519 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 3,391,353 shares. The stock had previously closed at $4.19.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Prime Medicine in a research report on Friday, September 25th. BMO Capital Markets initiated coverage on Prime Medicine in a research report on Tuesday, August 18th. They set an “outperform” rating and a $9.00 target price for the company. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. Wall Street Zen raised Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, Citigroup reiterated a “market outperform” rating on shares of Prime Medicine in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Prime Medicine has an average rating of “Moderate Buy” and an average price target of $7.86.
Check Out Our Latest Research Report on Prime Medicine
Prime Medicine Stock Performance
The firm has a market cap of $696.50 million, a PE ratio of -4.00 and a beta of 2.14. The stock’s 50 day simple moving average is $3.71 and its 200 day simple moving average is $3.51.
Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $4.21 million for the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. As a group, analysts anticipate that Prime Medicine, Inc. will post -0.97 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRME. Alphabet Inc. purchased a new position in shares of Prime Medicine during the second quarter worth approximately $61,116,000. BlackRock Inc. purchased a new stake in shares of Prime Medicine in the 2nd quarter valued at $35,432,000. ADAR1 Capital Management LLC purchased a new stake in shares of Prime Medicine in the 2nd quarter valued at $7,371,000. Redmile Group LLC bought a new position in shares of Prime Medicine during the 1st quarter valued at $5,536,000. Finally, Bank of America Corp DE bought a new position in shares of Prime Medicine during the 2nd quarter valued at $3,621,000. 70.37% of the stock is currently owned by hedge funds and other institutional investors.
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Prime Medicine
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
